Prieto, Camila
Nguyen, Diu T. T. http://orcid.org/0000-0001-8328-0009
Liu, Zhaoqi
Wheat, Justin
Perez, Alexendar
Gourkanti, Saroj
Chou, Timothy
Barin, Ersilia
Velleca, Anthony
Rohwetter, Thomas
Chow, Arthur
Taggart, James
Savino, Angela M.
Hoskova, Katerina
Dhodapkar, Meera
Schurer, Alexandra
Barlowe, Trevor S.
Vu, Ly P.
Leslie, Christina http://orcid.org/0000-0002-4571-5910
Steidl, Ulrich
Rabadan, Raul http://orcid.org/0000-0001-7946-9255
Kharas, Michael G. http://orcid.org/0000-0002-1165-6991
Article History
Received: 4 June 2020
Accepted: 11 May 2021
First Online: 5 July 2021
Competing interests
: M.G.K. discloses the following relationships and financial interests: 28-7 Therapeutics (Provision of Services, uncompensated) and Accent Therapetics (Provision of Services). U.S. has received research funding from GlaxoSmithKline, Bayer Healthcare, Aileron Therapeutics and Novartis, has received compensation for consultancy services and for serving on scientific advisory boards from GlaxoSmithKline, Bayer Healthcare, Novartis, Celgene, Aileron Therapeutics, Stelexis Therapeutics, Pieris Pharmaceuticals and Vor Biopharma and has equity ownership in and is serving on the board of directors of Stelexis Therapeutics. All other authors declare no competing interests.